Sanofi· @sanofi · X·· 2026-04-24精选AI 评分62
AI 导读
赛诺菲宣布，EMA下属CHMP已推荐批准其在研疗法，用于无复发的继发性进展型多发性硬化。赛诺菲称此举强化了其推进科学创新、应对未满足患者需求的承诺。
推荐理由
赛诺菲在研疗法获EMA下属CHMP推荐，用于无复发的继发性进展型多发性硬化，可据此了解该适应症的监管进展。
正文
#NEWS: The @EMA_News CHMP has recommended for approval our new investigational treatment for secondary progressive #multiplesclerosis without relapses, reinforcing our commitment to advance scientific innovation that address unmet patient needs.
Learn more ⬇️https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-24-10-09-46-3280641
来源：Sanofi · x.com